Update on Immunosuppression in Liver Transplantation

Area of Science:

• Hepatology
• Transplantation Immunology
• Pharmacology

Background:

• Liver transplantation (LT) is standard for end-stage liver disease and acute liver failure.
• Advances in immunosuppression have improved graft and patient survival.
• Long-term immunosuppressive drug use leads to significant adverse effects like infections and malignancies.

Purpose of the Study:

• To review current immunosuppression strategies in liver transplantation.
• To highlight the need for alternative approaches to mitigate drug-related toxicities.
• To discuss individualized therapy and novel agents in LT.

Main Methods:

• Review of current literature on immunosuppression in liver transplantation.
• Analysis of established and emerging immunosuppressive agents and their roles.
• Discussion of combination therapy and steroid-sparing strategies.

Main Results:

• Corticosteroids, calcineurin inhibitors (CNIs), antimetabolites, and mTOR inhibitors are key components of current regimens.
• CNIs remain crucial despite side effects, with antimetabolites used for sparing.
• Biologic agents are increasingly used for induction therapy.

Conclusions:

• Reducing long-term immunosuppressive drug burden is essential to minimize adverse effects.
• Individualized immunosuppression tailored to patient risk factors is crucial.
• Exploring novel agents and combination therapies offers promise for improved long-term outcomes in LT.